Abstract. Although down-regulation of WNT5A expression has been reported in some types of leukaemias, the level of WNT5A expression has not been assessed in leukaemia complete remission (CR) cases, the relationship among WNT5A expression level, the status of its promoter methylation, and the curative effect of leukaemia has not been reported, and the effect of WNT5A on cell proliferation has not been assessed. In this study, we analyzed WNT5A expression in various kinds of leukaemia cases, leukaemia CR cases, non-malignant hematopoietic (NMH) cases, as well as in leukemic cell lines and CD34 + cells. The methylation status of the WNT5A promoter and the levels of the Wnt5a protein were also studied. We also investigated the effect of Wnt5a on leukemic cell proliferation. WNT5A expression level was higher in NMH but lower in leukaemia cases compared to that in CR-cases (P<0.01), and was expressed at low level in leukemic cell lines K562, U937 and Jurkat. Wnt5a protein was positive in NMH, CR cases and CD34 + , but negative in leukaemia cases. WNT5A promoter was methylated in leukaemia cases and all leukemic cell lines, but not in NMH and CR cases. WNT5A expression was up-regulated after exposure to the demethylating agent 5-Aza-2'-deoxycytidine (Aza) in the K562, U937, Jurkat leukemic cell lines and in 83.3% (10/12) of CR patients after cure, respectively. The increased Wnt5a protein can inhibit K562 malignant proliferation and arrest cell cycle at the G2/M phase after exposure to Aza. These results indicate that WNT5A expression was restored in complete remission cases due to demethylation, and Wnt5a can inhibit leukaemic cell proliferation. We propose that WNT5A can act as a suppressor factor in leukemogenesis and can be used as a potential marker for curative effect assessment in leukaemia.
Introduction
Wnt proteins are a large secreted glycoprotein family that play important roles in mediating vital biological processes like embryogenesis, organogenesis and tumorigenesis (1) (2) (3) (4) . Wnt signaling has been divided into the canonical and noncanonical pathways. In the canonical pathway, Wnt binds to the Frizzle receptor leading to the inhibition of a multiple protein complex that otherwise can phosphorylate and degrade ß-catenin. The stabilized ß-catenin can thus translocate into nucleus and be responsible for the activation of gene transcription of Wnt/ß-catenin target genes including cyclin D1 and c-myc (5) (6) (7) (8) . Wnt5a, in the presence of specific FZ4, could also activate the canonical Wnt signaling pathway, and the overexpression of Wnt5a has ample opportunity to promote cell proliferation because of the up-regulation of cyclin D1 and c-myc. The non-canonical signaling pathway, although not completely understood, is independent of ß-catenin and mainly includes three defined pathways. The planar cell polarity: Vertebrate Wnt5a and Wnt11 initiate the signaling via Fz, which can operate through the cytoskeleton to control cell orientation and movement. This ability of Wnt5a to promote cell movement has crucial implications for normal development or cancer progression (9) . The Wnt⁄Ca 2+ pathways: Wnt5a and Fz2 may regulate intracellular Ca 2+ flux and levels which can lead to the activation of calmodulin-dependent protein Kinase II (CAMKII) and protein kinase C (PKC) (10) . This pathway also can stimulate the TAK1-NLK pathway to phosphorylate (11) , inactivate the active ß-catenin transcription complex and inhibit the activation of the canonical signaling (12, 13) . The ROR2 pathways: Wnt5a can bind and activate the ROR2 tyrosine kinase receptor resulting in the activation of the actin-binding protein, filamin A, and the JNK signaling pathway (11, 14) . This pathway also can stimulate the TAK1-NLK pathway to phosphorylate (11) and inactivate the active ß-catenin transcription complex (12, 15 (16) (17) (18) (19) , and Wnt5a has been reported to facilitate cell invasion in human metastatic melanoma (20) . However, the function of Wnt5a is complicated as recent findings suggested that it may have an anti-oncogenic role. Decreased expression of WNT5A was observed in endometrial carcinoma and thyroid carcinoma (21, 22) . Wnt5a can activate different Wnt signaling pathways, depending on which receptors are present at the cell surface (13, 15) . It may have a tumour suppressing or an oncogenic effect depending on the receptors in different cancer types. Hence, the presence or absence of these receptors may, to some extent, explain the conflicting role of WNT5A in different cancers. WNT5A also has tumor suppressor activity in hematopoietic tissue (23) . WNT5A is epigenetically silenced in hematologic malignancies, such as ALL, by aberrant methylation (24) . WNT5A down-regulation or silencing is also found in multiple hematologic tumor cell lines including nasal NK/T-cell lymphoma and NK leukaemia cell lines, leukaemia and Burkitt lymphoma (25) . However, the relationship between the expression level of WNT5A and the methylation status of its promoter in various kinds of leukaemia cases is not completely clear, especially in the leukaemia complete remission (CR) cases. Here, we analyzed WNT5A expression in bone marrow of complete remission cases (CR), leukaemia cases and non-malignant hematopoietic cases (as hyperplasia diseases of bone marrow), and analyzed WNT5A expression in CD34 + cells from umbilical cord blood (mainly including hematopoietic progenitor cells, a population of non-malignant proliferation cells) and leukemic cell lines (malignant proliferation cells), analysed the methylation status of the WNT5A promoter in leukemic cell lines, leukaemia cases, CR cases, and observed the effect of Wnt5a on leukemic cell line K652 proliferation after treatment with the Aza.
In this study, we demonstrated that WNT5A expression was down-regulated in leukaemia due to its promoter aberrant methylation but restored in complete remission cases owing to demethylating, and Wnt5a inhibited leukemic cell malignant proliferation. We propose that Wnt5a plays an important role in inhibiting leukemogenesis.
Materials and methods
Cell lines. Three leukaemia-derived cell lines (K562, U937, Jurkat) were preserved in our laboratory. Cells were grown at 37˚C under 5% CO 2 in humidified air in an RPMI medium (Gibco, Invitrogen Corp., USA) supplemented with 20% foetal bovine serum (HyClone, USA), 1% penicillin/streptomycin and 1% HEPES (Gibco).
Human subjects. We studied 68 leukaemia patients (37 male, 31 female), 18 
Negative WNT5A expression, no gel electrophoretic band in the RT-PCR assay. Positive WNT5A expression, visible gel electrophoretic bands in the RT-PCR assay.
Clinical characteristics of the patients are listed in Table I .
RNA extraction and RT-PCR.
Bone marrow mononuclear cells were lysed with cell lysis solution (139.6 mmol/l chlorine ammonia, 16.96 mM, Tris-buffer). Total RNA was isolated using TRIzol reagent (Invitrogen) and cDNA was synthesized from RNA by M-MLV reverse transcriptase (Toyobo, Japan) with oligo-dT primers (Sango Technology, China). The primer sequences of WNT5A genes were as follows: WNT5A upstream: 5'-TGTGGTTTAATGGTGCC TGA-3', WNT5A downstream: 5'-TTCGTCGTGCTCAAG GTATG-3'. GAPDH upstream: 5'-CATCACCATCTTCC AGGAGCG-3', GAPDH downstream: 5'-TGACCTTGCCC ACAGCCTTG-3'. The reaction mixture was first denatured at 94˚C for 5 min. The PCR conditions were as follow: 94˚C for 45 sec, 58˚C for 35 sec and 72˚C for 45 sec for 40 cycles (for WNT5A) or 28 cycles (for GAPDH), followed by 72˚C for 7 min. PCR products were visualized by ethidium bromide staining after agarose gel electrophoresis at sizes of 253 bp (WNT5A) and 443 bp (GAPDH), respectively. Expression of WNT5A was presented by the relative yield of the PCR products of the target sequence to that of the GAPDH gene. The semi-quantitative Formula is INT * mm
Treatment with the demethylating agent 5-Aza-2'-deoxycytidine.
Leukaemia-derived cell lines K562, U937, Jurkat were grown at a density of 1x10 6 cells⁄ml in 100 ml flasks with 10 ml of RPMI-1640 medium supplemented with 20% fetal bovine serum and maintained at 37˚C in a humid atmosphere containing 5% CO 2 . Cell lines were treated with 4 μM Aza (Sigma-Aldrich, Steinheim, Germany) for 2 days for methylation-specific assays, and the untreated cell lines were regarded as a control. After treatment, cells were washed in PBS, pelleted by centrifugation at 1500 rpm for 5 min and used for genomic DNA and RNA isolation. DNA was extracted using Tiangen DNA Mini Kit (Tiangen, China). One microgram of total RNA was used for cDNA synthesis by M-MLV reverse transcriptase (Toyobo, Japan) with oligodT primers (Sango Technology, China).
Methylation-specific PCR (MSP).
Analysis of the WNT5A (GeneBank: NC_000003) has revealed that WNT5A possesses a 229 bp CpG island located between nt47 and nt225, showing C+G content >60% and frequency of CpG island >0.6. Methylation status of the CpG islands in the WNT5A gene promoter was performed by genomic DNA bisulphite treatment followed by MSP. The primers for WNT5A-MD (M): 5'-GTATTTTTCGGAGAAAAAGTTATGC-3', WNT5A-MR: 5'-ACAACCGCGAATTAATATAAACG-3'. The primers for the unmethylated (U), WNT5A-UD: 5'-GGTATTTTTTGGAG AAAAAGTTATGTG-3', WNT5A-UR: 5'-CTACAACCAC AAATTAATATAAACATC-3'. PCR was carried out for 30 cycles consisting of denaturation at 95˚C for 1 min, annealing at 60˚C for 1 min, and extension at 72˚C for 1 min, followed by a final 7 min extension for all primer sets. The products were separated by electrophoresis on a 2% agarose gel. Results were always confirmed by repeat MSP assays after an independently performed bisulfite treatment.
Immunocytochemical staining. Cells were fixed on slide in polyformaldehyde for 30 min at 4˚C, rinsed and blocked for 1 h in 5% fetal bovine serum at room temperature. The cells were incubated with anti-Wnt5a polyclonal antibody (1:100 to 1:500, Santa Cruz Biotechnology) at 4˚C overnight or 37˚C for 60 min. After washing in PBS, the cells were incubated with a biotin-labeled secondary antibody (1:2000 to 1:10000, Sigma) for 1 h at room temperature, and DAB mixture was added and incubated for 20 min at room temperature. Normal rabbit serum in replace of primary antiserum is used as negative control. The slides were counterstained with hematoxylin.
MTT assay. Cell viability of the K562, U937, Jurkat was measured by the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) (Sigma Amresco, USA) before and after the treatment with Aza at the 24, 48, 72, 96 h. MTT was prepared as 5 mg/ml in phosphate-buffer solution at 37˚C just before use. A total of 900 μl MTT solution was added to each well and incubated at 37˚C temperature and 5% CO 2 and 95% relative humidity for 4 h. After incubation, MTT was aspirated and 250 μl per well of acidic solution of isopropanol was added to each well to dissolve the formazan precipitate. Subsequently, ELISA Reader (Bio-Rad Model 680, USA) read the optical densities of the plates at 570 nm.
Western blot assay. After the K562, U937 and Jurkat was treated with Aza for 48 h, cells were washed with ice-cold PBS twice and lysed on ice with lysis buffer (Sigma, USA). The insoluble material was removed by centrifugation at 4˚C (14000 x g for 10 min). Equal amounts of proteins were run on 10% SDS-PAGE gels and transferred to nitrocellulose membrane. After blocking with 5% skim milk, the membranes were subjected to immunoblotting with appropriate primary antibody (mouse monoclonal antibody Wnt5a IgG or Actin IgG) overnight at 4˚C. After washing and further incubation with secondary antibody (horseradish peroxidaseconjugated goat anti-mouse IgG) at 37˚C for 60 min, bands were visualized using an enhanced chemiluminescence system (Thermo Scientific, USA). Densitometric analysis of Western blots was carried out using Gel-Pro system (Bio-Rad, USA).
Flow cytometric analysis of cell cycle. After 48-h treatment with Aza (4 μM) cells were harvested, washed in cold PBS, fixed in 70% ethanol and stored at 4˚C. [Cells may be stored in 70% ethanol at -20˚C for several weeks prior to propidium iodide (PI) staining and flow cytometric analysis]. Cells were washed in PBS, 1 ml PI (50 μg/ml) of staining solution was added to the cell pellet and mixed well, then 50 μl of RNase A stock solution was added, followed by incubation for 3 h at 4˚C. Samples were stored at 4˚C until flow cytometry analyses.
Statistical analysis.
The results of RT-PCR were statistically analyzed using the one-way ANOVA test to determine the relationship of WNT5A mRNA expression mean values, respectively, among leukaemia cases, CR-cases, healthy cases and CD34 + cells. The results of MTT were statistically analyzed using the one-sample t-test. The results of WNT5A mRNA expression mean values of K562, U937, Jurkat before and after treated with Aza, respectively, were statistically ONCOLOGY REPORTS 25: 367-376, 2011 analyzed using the Paired-samples t-test. The results of cell cycle distribution of K562 cell were analyzed using the ¯2 test. SPSS 13.0 software was used. P<0.01 was considered statistically significance.
Results
Expression of WNT5A mRNA. The semi-quantitative mean value (x ± SD) of WNT5A expression was 0.374±0.125 in Immunocytochemistry staining of Wnt5a. The immunocytochemistry staining of Wnt5a was positive in healthy cases, CD34 + cells and CR-cases but was negative in leukaemia cases. All results of Wnt5a immunocytochemistry staining are shown in Fig. 7 .
Expression of WNT5A gene in non-malignant hematopoietic cases and corresponding status of their promoter methylation.
The expression of WNT5A transcripts was assessed by semi-quantitative RT-PCR in 27 non-malignant hematopoietic cases previously. Because the epigenetic events are important regulating mechanisms in gene transcripts, we decided to study the methylation status of the WNT5A promoter. By MSP, the WNT5A promoter was revealed to be unmethylated in non-malignant hematopoietic cases (NMH) in accordance with the positive WNT5A expression. The results are shown in Fig. 8 .
WNT5A promoter methylation in leukaemia patients is associated with underexpression of WNT5A transcripts.
Methylation of WNT5A promoter was observed in 69% (47/68) samples amongst all the leukaemia patients, and only in 8.6% (3/35) amongst all the leukaemia CR patients (data not show). In order to further study the relationship between methylation and WNT5A expression, we show MSP and expression analysis of WNT5A gene in 12 leukaemia cases before and after their complete remission (CR). Amongst 12 leukaemia cases, methylation of WNT5A promoter was observed in 75% (9/12) samples, the positive rate of WNT5A mRNA expression was 25% (3/12). In contrast with complete remission cases, methylation of WNT5A promoter was observed in 8.3% (1/12) samples, the positive rate of WNT5A mRNA expression was 91.7% (11/12) , only one complete remission case was found methylated of WNT5A promoter. The results are shown in Fig. 9 .
Expression of WNT5A gene in leukaemia-derived cell lines is regulated by promoter methylation.
In order to confirm the results of the MSP in NMH and leukaemia cases, we assayed 
Treatment of K562 cells with Aza leads to cell cycle arrest.
After 48-h treatment with Aza, K562 cells from different groups were collected and their cell cycle distribution was analyzed. These results suggest that demethylating agent Aza can induce K562 cell cycle arrest at G2/M phase. The results are shown in Fig. 12 .
Discussion
Various WNT family members play important roles in haematogenesis by controlling the proliferation of progenitor cells and might also affect the cell-fate decisions of stem cells. Therefore, WNT signaling is subject to strict molecular control, and dysregulated WNT signaling is implicated in the development of haematological malignancies. Previous studies have shown that reduction or absence of WNT5A expression is observed in some of the human primary leukaemia samples (23, (24) (25) (26) . In this study, we describe for the first time that the levels of WNT5A expression in different kinds of nonmalignant hematopoietic cases (NMH), leukaemia cases, leukaemia CR cases, leukemic cell lines and CD34 + from umbilical cord blood. We also assayed the methylation status of WNT5A promoter in NMH, leukaemia, and leukaemia CR. We compared the level of WNT5A expression and the methylation status of WNT5A promoter in these cases before and after complete remission, respectively.
The results showed that WNT5A expression was downregulated in leukaemia cases due to the methylation of its promoter and was up-regulated in NMH and CR cases due to the demethylation of their promoter. The results indicated that the level of WNT5A expression was correlated with the methylation status of its promoter in leukaemia cases. The relationship between methylation and expression of WNT5A was further explored by the fact that when the leukemic cell lines K562, U937 and Jurkat were treated with Aza (a demethylating agent, which can induce demethylation of the WNT5A promoter region), up-regulation of WNT5A mRNA was observed. It was confirmed that the WNT5A expression was epigenetically regulated by methylation status of its promoter. In order to elucidate the relationship between the leukemic cell proliferation and up-regulation of WNT5A expression, K562 cell proliferation was studied by MTT assay and flow cytometry after treatment with Aza. Treatment of Aza decreased the viability of K562 cell in a timedependent manner. After 48-h treatment with Aza, the viability of K562 cell was significantly decreased, and the demethylating agent can induce K562 cell cycle arrest at G2/M phase. These results suggest that Aza can induce demethylation of the WNT5A promoter, which can upregulate the WNT5A expression. The up-regulation of Wnt5a level inhibits the K562 cell malignant proliferation, and arrests the K562 cell cycle at G2/M phase. Our findings suggest that Wnt5a can act as a suppressor factor in leukemogenesis. The conclusion is also supported by the fact that Wnt5a expression is resumed in leukaemia CR cases.
Román-Gómez et al reported that expression of the Wnt inhibitors sFRP1, sFRP2, sFRP4, sFRP5, WIF1, Dkk3, and Hdpr1 was down-regulated due to abnormal promoter methylation in ALL cell lines and samples from patients with ALL (27) . Román-Gómez et al (27) , Ying et al (25) and Martín et al (26) also reported that the expression of WNT5A can be down-regulated due to abnormal promoter methylation in leukaemic cell lines or leukaemia. In the present study, K562 cell proliferation was inhibited after treatment with Aza. It is possible that both the up-regulation of WNT5A and the Wnt inhibitors can inhibit the K562 cell proliferation through inhibiting the canonical Wnt pathway. To determine which is the case, we applied the polyclonal antibody of WNT5A to the K562 cells treated with Aza as a control. We found that the cell viability was significantly lower at 48, 72, and 96 h after the treatment of Aza in the group of K562+Aza (P<0.01), but was not significantly different in the groups of K562+Aza+Ab or K562+Ab, compared to the normal medium group. The cell cycle was arrested at G2/M phase at 48 h after treated by Aza in group of the K562+Aza, but not in the groups of normal medium, K562+Aza+Ab and K562+Ab. The results confirmed that Wnt5a can inhibit the K562 cell malignant proliferation. Further study is needed to investigate the mechanism that cause the K562 cell cycle arrest at G2/M phase after treatment with Aza.
In addition, our research also showed that the WNT5A expression level of CD34 + cell was higher than that of leukaemia cases, but lower than that of NML. The level of WNT5A expression in CD34 + may be related to maintaining the hematopoietic progenitor cells moderate proliferation potential. The hematopoietic progenitor cells are responsible for the continuous production of blood cells. Thus, the proliferation potential is higher than that of the mature blood cells, but lower than that of the malignant proliferation in leukaemic cells. The level of WNT5A expression (higher than that of malignant proliferation leukaemic cells but lower than that of non-malignant proliferation cell of NML cases) may be one of the mechanisms which adjust the moderate proliferation potential of hematopoietic progenitor cells.
Currently, leukaemia diagnosis, treatment as well as prognosis evaluation are mainly based on the morphology analysis performed in the clinical laboratory. There are limitations for the morphology diagnosis. First, it can not be used for early diagnosis, since the morphological changes always lag the molecular alterations, and it generally requires more than 10 6 malignant cells for reliable detection. Second, the accuracy of the diagnosis is compromised due to the objectivity of the method itself, as well as the complexity of cell morphology resulting from variations among individuals. In China, for example, according to the incomplete statistics, the diagnosis accuracy through morphological observation of patient bone marrow cells is only 70%.
Thus, additional diagnostic methods are needed in order to improve the diagnostic accuracy. Molecular biomarkers have become promising diagnostic tools. For example, the measure of fusion gene expression is used in diagnosis of leukaemia or predicting its relapse. It is well established that measuring of fusion gene expression of BCR-ABL, PML-RAR·, and AML-ETO is used in the diagnosis of certain CML, APL and AML, respectively. However, since these fusion genes are limited to certain types of leukaemia, a broad spectrum diagnosis marker and the index of curative effect assessment is needed that can diagnose leukaemia at an early stage reflecting the change required in treatment. Both our research and past reports have showed that there are remarkable differences in Wnt5a expression levels not only between normal and solid tumor tissues (16) (17) (18) (19) , but also between normal or non-malignant hematopoietic tissue and most blood malignancies (20) (21) (22) 24, 28) . Loss of expression of Wnt5a may be one of the reasons that hematopoietic cells obtain malignant proliferation ability. Therefore, the complete remission leukaemia and non-malignant hematopoietic cases may be distinguished from the human primary leukaemia by the expression level of WNT5A, the level of WNT5A expression can reflect the effect of treatment. We propose that WNT5A can act as a suppressor factor in leukemogenesis and can be used as a potential marker for curative effect assessment in leukaemia.
